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OBJECTIVES: The purpose was to estimate the EI of VM
in the United States from payer and societal perspectives.
METHODS: The EI of VM was estimated by applying
the cost and probability estimates of events in a decision
analytic framework (DAF). DAF development and prob-
ability of events were obtained from an expert panel. Di-
rect medical costs were estimated by charge data ob-
tained from the 1996 Pennsylvania Medicaid database
and the Drug Topics Red Book. Indirect costs were ob-
tained in terms of activity restricted days (ARDs) as esti-
mated by the panel. ARDs were defined as the average
number of days patients with VM missed school/work or
normal activities. Monte Carlo simulations were used to
generate the distribution of charges for estimating the EI
of VM on a per patient basis. The per patient EI was then
extrapolated to the US population. Sensitivity analyses
(one-way) were conducted by varying the probability val-
ues at the dominant nodes, nodes with high-cost, and
nodes with the largest ranges.
RESULTS: An episode of VM poses direct medical costs
to payers ranging from $4500 to $5700 in adult patients
and $5000 to $5300 in pediatric patients. Similarly, an
episode of VM poses an average of 5.6 to 7.5 ARDs.
These results were stable across the sensitivity parameters
tested.
CONCLUSIONS: Management of VM imposes a sizable
economic burden from both the payer and societal per-
spectives. Based on a conservatively estimated 250,000
annual cases of VM in the United States, the economic
burden to payers in terms of direct costs exceeds $1 bil-
lion per year. The additional economic burden in terms
of indirect costs to society would approximate 1.5 mil-
lion ARDs.
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Prior estimates of the cost of epilepsy have been based on
expert panels and decision-analysis models, but not on
national data.
OBJECTIVES: To estimate annual medical resource use
and payer costs of inpatient and outpatient medical care
related to epilepsy.
METHODS: Using three sources of national survey data
from 1992 to 1996—1) the Healthcare Cost and Utiliza-
tion Project Nationwide Inpatient Sample (NIS), 2) the
National Ambulatory Medical Care Survey (NAMCS),
and 3) the National Hospital Ambulatory Medical Care
Survey (NHAMCS)—we identified all inpatient admis-
sions and outpatient encounters with a primary ICD-9-
CM diagnosis code, and alternatively, any diagnosis code,
of epilepsy (345.1–345.9) or convulsions (780.3). We
then assigned an allowed charge to each encounter by
matching it to an encounter in Medicare’s Standard Ana-
lytic File (SAF). Annual rates of medical resource use and
payer costs were then estimated, by diagnosis and payer
type.
RESULTS: The annual payer cost of inpatient and outpa-
tient care with a primary diagnosis of epilepsy or convul-
sions was approximately $4.8 billion. Medicare accounted
for 35% of these costs followed by private insurers/HMOs
(28%) and Medicaid (27%). Encounters with a primary
diagnosis of convulsions accounted for 73% of costs,
while those coded as epilepsy accounted for the remaining
27%. Annual cost of care with any diagnosis code for epi-
lepsy or convulsions was $22 billion.
CONCLUSION: Even without accounting for medica-
tions, the costs of epilepsy appear higher than previously
estimated. This analysis provides a national estimate of
the inpatient and outpatient costs of epilepsy.
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Colon cancer is a common cause of malignancy in men
and women. The incidence has been increasing over the
past several decades. Fecal occult blood testing has been
shown in several randomized controlled studies to reduce
the rate of colorectal cancer. The US Preventive Task
Force has recommended universal screening after the age
of 50. More than 150,000 new cases of colon cancer are
diagnosed each year. The mortality rate continues to be
greater than 50% in these diagnosed cases. Various fecal
occult blood tests (FOBT) used in screening colorectal
cancer have reduced mortality by 15–30%.
OBJECTIVE: The purpose of this study was to assess the
effectiveness of fecal occult blood testing in reducing the
mortality rate from colorectal cancer as part of a man-
aged care program. The suggested number of patients
needed for screening to prevent one death from colon can-
cer is 1374 for 5 years. The cost of FOBT is relatively in-
Abstracts 145
expensive as compared to colonoscopy or barium enema,
which may cost more than $1000.00. A guaiac-based test
was utilized costing approximately $0.81 per test.
METHOD: Patients in primary care were included in
routine preventive screening to include FOBTs. We eval-
uated 2021 FOBTs during FY1997.
RESULTS: $1637.01 was spent screening 2021 patients.
Four asymptomatic patients were detected to have colon
cancer as a result of this screening. One potential death
was prevented for every 505.25 patients screened.
CONCLUSION: In certain managed care patient popula-
tions, this may be an even more cost-effective approach
in colorectal screening.
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OBJECTIVE: In a cost analysis we compared the socio-
economic relevance of diagnostic screening to differenti-
ate type 2 diabetes mellitus patients with autoantibodies
from type 2 patients without screening. As the prevalence
of antibodies is—compared to older or younger pa-
tients—enhanced at the age of 30 to 45, this analysis fo-
cussed on this population of diabetes mellitus type 2 aged
30 to 45 years.
METHODS: In a decision tree analysis two groups of pa-
tients with diabetes mellitus one with and one without
screening were compared. Endpoints were diabetes associ-
ated late complications as myocardial infarction, stroke,
proliferative nephropathy, proliferative retinopathy, ma-
jor amputation caused by diabetic foot lesion. Costs of di-
abetes treatment are calculated over a period of 20 years
considering the high prevalence of late complications after
20 years duration of the disease. Costs of diabetes-associ-
ated late complications are analyzed over a period of 1
year. This analysis included both direct and indirect costs.
The model examined the costs from the perspective of the
payer (German sickness fund).
RESULTS: Over a period of 20 years total costs for diag-
nostic screening per patient amounts to DM 31,278 in-
cluding DM 7799 for direct and DM 23,479 for indirect
costs. The control group revealed total costs per patient of
DM 35,290 while direct costs amount to DM 10,984 and
indirect costs to DM 24,306. The projection of the total
population results in a cost saving potential of DM 2.6 bil-
lion after investment of DM 22.8 million for screening.
The model’s robustness was proved in sensitivity analyses.
CONCLUSION: Autoantibody screening of 30- to 45-
year-old diabetes mellitus patients reduces healthcare ex-
penditures as it decreases the prevalence of diabetes asso-
ciated late complications.
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Literature indicates that mammography screening is cost-
effective for detecting early-stage breast cancer in high-
risk populations compared to other medical interven-
tions. Mammographic interpretations are typically lim-
ited to single readers and studies do not necessarily ac-
count for the costs and effects associated with double
reading (mammography interpretation by two radiolo-
gists), when practiced. Compared to single reading (SR),
double reading (DR) has been shown to increase sensitiv-
ity although its effects on specificity and on costs and
outcomes are not clear.
OBJECTIVE: To review current literature regarding SR
and DR to assess 1) the value of DR and 2) the need for
cost-effectiveness analyses of DR versus SR.
METHODS: A review of clinical and economic literature
of SR and DR was performed.
RESULTS: A limited number of studies indicate that the
cost-effectiveness of DR depends upon the approach used.
Specifically, a difference emerges between consensus DR
(where two radiologists achieve agreement on interpreta-
tion) and independent DR. Overall, findings show that con-
sensus DR may be cost-effective compared to SR by increas-
ing sensitivity (by 5% to 15%) while decreasing the recall
rate (or increasing specificity) by 2% to 10%. In contrast,
independent DR appears to increase the recall rate at added
costs and therefore, may not be cost-effective.
CONCLUSION: An increase in sensitivity should be
weighed against the decrease in specificity associated with
DR. Additional cost-effectiveness analyses of DR (both in-
dependent and consensus) compared to SR should be con-
ducted to determine the overall value of DR and to guide
health policy decision-making. Cost-effectiveness analy-
ses could also be conducted to evaluate the value of new
computer-aided detection systems designed to improve
sensitivity without compromising specificity.
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OBJECTIVE: Mammography has been well established
as a cost-effective tool in breast cancer screening. How-
ever, low compliance has been a major obstacle to its suc-
cess. The current study is to compare the characteristics
of all programs that aimed at improving mammography
compliance and to examine their effectiveness on an ag-
gregate basis.
